Cure Ventures

High-Level Overview

Cure Ventures is a Boston-based venture capital firm dedicated to accelerating the development of curative therapies through early-stage investments in life sciences and biotechnology. The firm’s mission centers on company formation—partnering with visionary scientists and entrepreneurs to build startups from the ground up, with a focus on groundbreaking therapeutics that address significant unmet patient needs. Cure Ventures’ investment philosophy emphasizes de-risking science at the seed stage, leveraging genetic validation to guide drug development, and embedding experienced operators within portfolio companies to drive day-to-day decision-making. Their core sectors include new therapeutics, genetic medicine, and advanced biotechnologies, and their hands-on approach has positioned them as a catalyst for innovation in the life sciences startup ecosystem.

Origin Story

Founded in 2021, Cure Ventures emerged from a collective of industry veterans with deep roots in landmark labs and historic biotech companies. The firm was co-founded by David Fallace, who serves as Managing Partner, alongside a team of accomplished scientists and operators including Dr. Michael Aberman and Dr. Milenko Cicmil. Cure Ventures was established with the vision of reimagining how early-stage biotech companies are formed and scaled, combining scientific rigor with operational expertise. Their evolution has been marked by a deliberate focus on company creation rather than just capital provision, setting them apart in a crowded venture landscape.

Core Differentiators

• De Novo Company Formation: Cure Ventures specializes in building companies from inception, working closely with scientists to identify and validate breakthrough ideas.
• Genetic Validation Integration: The firm uses genetic validation as an iterative process to guide drug development, increasing the probability of clinical success and reducing costly failures.
• Embedded Operator Model: Cure deploys world-class industry veterans directly into portfolio companies, providing hands-on operational support and strategic mentorship.
• Seed Funding with Follow-Through: Cure provides seed capital to de-risk early science and commits to co-leading subsequent Series A and B rounds, ensuring continuity and long-term partnership.
• Network Strength: Backed by a diverse syndicate of institutional investors—including public pension funds, foundations, hospital systems, and family offices—Cure brings both capital and strategic connections to its portfolio.

Role in the Broader Tech Landscape

Cure Ventures is riding the wave of a biotech renaissance, where advances in genetic medicine, AI-driven drug discovery, and precision therapeutics are transforming healthcare. The timing is critical: as the cost of drug development continues to rise and the need for curative therapies grows, Cure’s model addresses a key bottleneck—de-risking early-stage science. By focusing on company formation and embedding operational expertise, Cure is helping to bridge the gap between academic discovery and commercial success. Their approach is influencing the broader ecosystem by setting a new standard for how venture capital can actively shape the trajectory of life sciences startups, fostering a culture of collaboration and scientific integrity.

Quick Take & Future Outlook

Cure Ventures is poised to play an increasingly influential role in the life sciences sector as the demand for curative therapies accelerates. Their unique blend of scientific rigor, operational involvement, and long-term partnership positions them to back the next generation of breakthrough biotech companies. As trends like personalized medicine, gene editing, and AI-driven drug discovery continue to mature, Cure’s model will likely become a blueprint for how venture capital can drive both innovation and impact. Their journey reflects a broader shift in the startup ecosystem—where capital alone is no longer enough, and true value is created through deep collaboration and shared vision.